Drug Type Autologous CAR-T |
Synonyms Anti-CD19 CAR-T cell therapy - Novartis/University of Pennsylvania, HUCART19, CTL 119 + [2] |
Target |
Action modulators |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), T lymphocyte replacements |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adult Lymphoblastic Lymphoma | Phase 2 | United States | 25 Jan 2023 | |
CD19-positive B-cell acute lymphoblastic leukemia | Phase 2 | United States | 25 Jan 2023 | |
Recurrent B Acute Lymphoblastic Leukemia | Phase 2 | United States | 25 Jan 2023 | |
Pre B-cell acute lymphoblastic leukemia | Phase 2 | United States | 18 Jan 2019 | |
Refractory Adult Acute Lymphoblastic Leukemia | Phase 1 | United States | 27 Sep 2018 | |
Plasma Cell Leukemia | Phase 1 | United States | 09 May 2018 | |
Plasma Cell Leukemia | Phase 1 | United States | 09 May 2018 | |
Relapse multiple myeloma | Phase 1 | United States | 09 May 2018 | |
Relapse multiple myeloma | Phase 1 | United States | 09 May 2018 | |
Chronic lymphocytic leukaemia refractory | Phase 1 | United States | 29 Jan 2016 |
Not Applicable | 57 | gyjbytmbud(zenjjtockz) = hnwtofxnmi uxexrovpwc (ernzdgpbkz ) View more | Positive | 08 Dec 2024 | |||
gyjbytmbud(zenjjtockz) = xtorexskwc uxexrovpwc (ernzdgpbkz ) View more | |||||||
Phase 1 | 19 | CTL-119+Ibrutinib | tftimnydpf(lkyootqoef) = 18pts cytokine release syndrome (CRS; grade 1-2 in 15pts) and 5pts neurotoxicity (grade 1-2 in 4pts, grade 4 in 1pt) mxnhlmbibx (cxfbeumbsg ) | Positive | 29 Mar 2022 | ||
Phase 1 | 38 | (CAR-naive) | aeosuhqgck(itlxvuteom) = Cytokine release syndrome (CRS) was observed in 34/38 patients and mild in most patients (grade 1, n=6; grade 2, n=23). Four patients experienced grade 3 CRS requiring supplemental oxygen and/or low-dose vasopressor support and 1 experienced grade 4 CRS requiring high-dose vasopressor and ventilatory support. ialmijbiym (fukyzfoxvo ) | Positive | 07 Dec 2017 | ||
(retreatment) | |||||||
Early Phase 1 | 10 | Ibrutinib+CD19 CAR-T cells | xfgyxhfurl(lsqvcebiwd) = in 9 pts; gr1 in 2, gr2 in 6 and gr3 in 1 pt. One pt developed gr4 tumor lysis syndrome udblvzekvg (vaexwxqkcn ) | Positive | 05 Jun 2017 |